Correlation of sCD40L Level with Force Vital Capacity Value in  Restrictive Lung Disease of Systemic Sclerosis Patients by Salim, Susanto et al.
Original Article
20 Indonesian Journal of Rheumatology 2018; Vol 10 No.1
Correlation of sCD40L Level with Force Vital
Capacity Value in Restrictive Lung Disease of 
Systemic Sclerosis Patients
Susanto Salim,1 Rachmat Gunadi Wachjudi,1 Sumartini Dewi1
1 Internal Medicine 
Department, Faculty of 
Medicine, Universitas 
Padjadjaran,
dr. Hasan Sadikin 
General Hospital
Corresponding author: 
Susanto Salim MD, 
susantolim84@gmail.
com
autoimmune connective tissue disease that involving 
many organs. The etiology of this disease is still 
not well known.1-3 Lung is common organ involved 
in systemic sclerosis patients, such as Interstitial 
Lung Disease (ILD) and pulmonary arterial 
hypertension.4 Systemic Sclerosis patients suffered 
with ILD tend to has lower quality of life compared 
to healthy person.5 European Scleroderma Trials 
and Research (EUSTAR) group reported ILD was a 
major cause of death in systemic sclerosis. Data of 
5800 systemic sclerosis patients showed as much as 
35% deaths caused by pulmonary fibrosis, 26% by 
pulmonary arterial hypertension and 4% by kidney 
disorder.6
ILD is difficult to diagnose, especially in 
developing country, due to unavailability of High 
Resolution Computed Tomography (HRCT) 
scanning which is the gold standard for diagnosing 
ILD.4,7,8 Moreover, it is not affordable for the 
most patients. Other pulmonary function tests 
are more commonly used as initial screening of 
ILD in systemic sclerosis patients in our center.4,7 
Those PFT instruments consist of test for diffusing 
capacity of the lung for carbon monoxide (DLCO), 
spirometry to define forced vital capacity (FVC), 
etc. The pulmonary function tests (PFT) play as 
key role to determine the severity of pulmonary 
complication in SSc patients. FVC is one of the 
common test which use to determine the severity of 
restrictive abnormality in ILD.8
T-cells trigger fibroblasts activation which 
causing fibrosis process in systemic sclerosis 
patients. Activated CD4 T-cells will express CD40 
ligand (CD40L/CD154) that binds to CD40 on 
the surface of the B-cells. T cells will produce 
cytokines and stimulate fibroblast to start fibrosis 
cascade as the main pathogenesis of systemic 
sclerosis.9 CD40L is suggested playing role in 
fibrosis cascade. CD40L can be cleaved from the 
cell surface, releasing a soluble CD40L (sCD40L) 
which is biologically active.10,11 Allanore, et 
al reported  an increase of plasma sCDL40 
associated with vascular complication in systemic 
sclerosis patients. Instead, other studies reported 
controversially role of CD40-CD40L bond in 
pulmonary fibrosis.11,12
Aim of this study is to analyze the correlation 
of sCD40L level with FVC value in restrictive lung 
Abstract
Background: Interstitial Lung Disease (ILD) is one of 
the major cause of morbidity and mortality in Systemic 
Sclerosis (SSc). The gold standard to diagnose ILD is 
using High Resolution Computed Tomography (HRCT) 
scan. HRCT scan need a lot of cost and not always 
available, so another diagnosing test is needed as an 
alternative modality to diagnose ILD. ILD is a restrictive 
lung disease caused by lung fibrosis which is proved 
by the decrease of Forced Vital Capacity (FVC) in 
spirometry, and followed by the increase of soluble 
CD40L (sCD40L) level in plasma. This sCD40L may 
become a potential biomarker to evaluate lung fibrosis 
in SSc patients. The aim of this study is to analyze the 
correlation of sCD40L levels with FVC score  in SSc 
patients with restrictive lung disease.
Method: This cross sectional study was enrolled by the 
SSc patient who has restrictive lung disease based on 
spirometry test, at Rheumatology outpatient clinic dr. 
Hasan Sadikin Hospital from May 2015 to May 2016. All 
subject took underwent history, physical examination, 
spirometry and blood test for sCD40L. Data were 
analyzed using Pearson correlation.
Result: There were 38 subjects involved in this study, 
dominated bywoman (92.1%) with mean age 41(±11) 
years. Subjects consist of 22(57,9%) with limited SSc, 
16(42,1%) with diffuse SSc patients and 33 subjects 
treated with DMARD. Mean sCD40L serum in this study 
was 6.690,3(±2.377,3) pg/mL, with no statistical 
difference between limited and diffuse type (p=0.154). 
Mean FVC score in this study was 58.2(±10,8). There 
was no significant correlation between sCD40L serum 
with FVC (r=0.058; p=0.366). There was weak 
correlation on DMARD naïve subject between sCD40L 
serum and FVC (r=0.058; p=0.366) but statistically 
insignificant. There was no significant correlation 
between sCD40L serum with mRSS (r=0,066; 
p=0,346).
Conclusion: This study founds no correlation between 
sCD40L with FVC in SSc at dr. Hasan Sadikin Hospital.
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Introduction
Systemic Sclerosis (SSc) is a chronic progressive 
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disease of systemic sclerosis patients. 
Method
This cohort retrospective study enrolled the systemic sclerosis 
patients who had restrictive lung disease based on spirometry 
test. Data were collected from outpatient subjects at clinic 
rheumatology, Hasan Sadikin General Hospital from May 
2015 to May 2016. The inclusion criteria were patients who 
diagnosed with systemic sclerosis based on ACR/EULAR 
2013 criteria with restrictive lung disorders and willing to 
participate in this study, includes carried out blood test and 
spirometry examination. Exclusion criteria were patients who 
diagnosed with other autoimmune diseases and/or diagnosed 
with restrictive lung disease other than ILD through history, 
physical examination and history from previous medical 
records.
This study used two step of data collection. Initial step 
was screening to get subjects who meet the inclusion and 
exclusion criteria. The next step was venous blood sampling 
to determine the sCD40L level followed by spirometri test to 
evaluate FVC value. Then data was analyzed with Pearson 
correlation test.
Result
We included 38 patients in this study. Characteristics of the 
subject are shown at table 1. 
Table 1. Characteristics of Subjects
Characteristics
All Subjects
n=38
Limited Type
n=22 (57.9%)
Diffuse Type
n=16 (42.1%)
Age (mean ± SD) years 41 ± 11
Sex 
Male (n%) 3 (7.9)
Female (n%) 35 (92.1)
Treatment History
Methotrexate (n%) 33 (86.8)
Steroid (n%) 33 (86.8)
Cyclophosphamide (n%) 2 (5.3)
DMARD-naïve (n%) 5 (13.2)
mRSS (median, range) 17 (4 – 36) 12 (4 – 23) 27 (10 – 36)
FVC (mean ± SD) 58.2 ± 10.8 57,1 ± 12,7 59,6 ± 7,5
sCD40L (mean ± SD) (pg/mL) 6690.3±2377.3 6218,0 ± 2170,7 7339,8 ± 2562,5
The median of modified Rodnan Skin Score (mRSS) is 17 
and has range 4 to 36. Mean of FVC by spirometry examination 
was 58.2 + 10.8. The most were 15 (40%) moderate restrictive 
lung patients, 10 (26%) severe restrictive lung patients, 
8 (21%) moderate to severe restrictive lung patients, and 5 
(13%) mild  restrictive lung patients. Mean of sCD40L was 
6690.3±2377.3 pg/mL. There were no statistically different 
of sCD40L level and FVC value between diffuse type and 
limited type systemic sclerosis subjects.
There was five (13.2%) subjects who were for the first time 
diagnosed as systemic sclerosis and had never taken DMARD 
treatment before this study. mRSS score was higher in 
DMARD-naïve patients (p = 0.036, Mann-Whitney) sCD40L 
and FVC had no different between DMARD patients and 
DMARD-naïve patients shown in table 2.
Tabel 2. Difference between DMARD and DMARD-naïve patients
Variabel DMARD-naïven=5
DMARD
n=33 p-value
mRSS (median, range) 32 (15 – 36) 14 (4 – 34) 0.036
sCD40L (mean ± SD) 5909.8 ± 783.8 6808.6 ± 2519.5 0.438
FVC (mean ± SD) 58.4 ± 9.1 58.1 ± 11.1 0.958
Bivariate test was used to analyze correlation between 
sCD40L level and FVC value revealed that sCD40L was not 
correlated with FVC (r=0.058, R2 = 0.0034, p=0.366, Pearson 
correlation). Figure 1 show scatter diagram of this study.
Figure 1. Scatter diagram between sCD40L and FVC
There was weak correlation on DMARD naïve subject 
between sCD40L serum and FVC (r=-0.225; p=0.358, Pearson 
correlation) but not significant as shown in table 3.
Tabel 4. Bivariate Analysis between sCD40L and FVC in DMARD 
and DMARD-naïve Patients
Variable Patients
FVC
r p-value
sCD40L
DMARD-naïve -0.225 0.358
DMARD 0.069 0.351
Discussion
Average age of the subjects was 41±11 years, it is in accordance 
with the onset of systemic sclerosis disease which the highest in 
the fourth and fifth decade.13,14 Mean age was smaller compared 
to the research conducted by Allanore et al (50 subjects) 57±11 
years and Komura et al (49 subjects) 51.4±15.6 years but in 
accordance with study on Asian population in Singapore by 
Low et al (200 subjects), namely 46±14.9 years.11,15,16 This 
difference maybe due to race differences in both populations. 
So, age of systemic sclerosis patient in Caucasian population 
is older than in Asian populations.
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Most of the subjects were women (92.1%). These results 
were differed by the proportion of women and men incidence 
in US that reached 3−5:1.1,14,17 But, similar to the result 
obtained by Komura, et al. study in Asia (92%) and Low 
research in Singapore (86%).15,16
Mean FVC value by spirometry was 58.2±10.8%. All 
subject as restrictive lung disorder that may be a pulmonary 
fibrosis. There was no difference in FVC value between limited 
type and diffuse type subjects (p=0.482). Abnormalities of 
pulmonary fibrosis is more common in diffuse type since it is 
a rapidly progressing disorder that affects a large area of the 
skin and compromises one or more internal organs including 
lung. Expression of antinuclear antibody is more dominant 
in diffuse type SSc compared to the limited type.1 FVC 
examination can be used as an initial screening test but the 
incidence of pulmonary fibrosis may not be used as the gold 
standard to diagnosis pulmonary fibrosis.
Mean of sCD40L levels in our study were 6690.3±2377.3 
pg/mL. This is higher when compared with control values  in 
Allanore, et al study (median sCD40L 79 (50−118) pg/mL) 
and Salibi, et al. study (mean sCD40L 717 pg/mL). sCD40L 
levels in our study is also higher than sCD40L level in systemic 
sclerosis patients in Allanore, et al. study with a median 
sCD40L 495 (10−2690) pg/mL and Salibi, et al study with 
a mean sCD40L 1564 pg/mL.11,18 This difference happened 
due to the difference subjects involved in Allanore, et al study 
used all systemic sclerosis patients with or without pulmonary 
complication, while in the Salibi, et al study, the subjects 
were included the lung fibrosis subjects with any underlying 
disease. Whereas the subjects in our study were the systemic 
sclerosis patients with restrictive lung disorders. CD40L 
is believed to play role in the fibrosis cascade of systemic 
sclerosis patients. CD40-CD40L bond between T-cells and 
B-cells trigger proliferation and differentiation of B-cells 
into plasma cells and forms a bond autoantibody.19,20 CD40-
CD40L activates the proliferation of fibroblasts, produces 
pro-inflammatory cytokines, and begins fibrosis process.21,22 
Komura and Fukasawa reported the increase of plasma CD40 
protein due to CD40 expression on fibroblasts surface in 
systemic sclerosis patients.15,21 CD40L can be cleaved from 
cell surface and dissolved as a soluble CD40L on plasma that 
biologically active.10,23
From our study, we found no statistically correlation 
between sCD40L level and FVC (r=0.058, R2=0.0034, 
p=0.366). This is consistent with Allanore, et al study that 
reported lack correlation between sCD40L levels with 
pulmonary fibrosis and carbon monoxide diffusing capacity 
(DLCO).11 Other study by Salibi, et al reported a significantly 
increasing of sCD40L levels in pulmonary fibrosis patients 
when compared to the healthy population (p < 0.05).18 Salibi, 
et al also reported a correlation sCD40L level with FVC 
(R2=0.16, r=0.4) but not significantly related (p=0.16).12
There are some differences between our study and the 
study conducted by Allanore, et al or Salibi, et al. This study 
included 38 subjects while Allanore, et al study followed by 
50 subjects and Salibi et al study followed by 13 subjects. This 
study uses retrospective cohort while the two other studies 
using cross sectional method. This research together with 
Salibi, et al analyzed the correlation of sCD40L levels with the 
value of FVC, while Allanore, et al analyzed the association of 
sCD40L levels with the incidence of pulmonary fibrosis and 
DLCO. 
Other difference is our study and Allanore, et al study 
used systemic sclerosis patients, while Salibi, et al. research 
used all subjects with pulmonary fibrosis. Study conducted 
by Allanore, et al only involve systemic sclerosis patients 
who have not received immunosuppressive therapy, while 
in our study, only five subjects who have not received 
immunosuppressive therapy and the remaining subjects have 
been treated with methotrexate.
Different level of sCD40L may be affected by several 
conditions in our subject settings. First, 83.8% subject has been 
treated with DMARD (methotrexate, cyclophosphamide). 
Methotrexate could interfere activation of T-cell that might 
affect the level of sCD40L.24 Second, we measured sCD40L 
to represent the activity of CD40L, because sCD40L has the 
CD40L biologic activity. However, there were not any data 
about the equivalent of sCD40L level on serum and CD40L 
level on T-cell. Third, many factors could interfere the result 
of FVC measurement such as age, sex, weight, height, chest 
abnormality. Fourth, disease activity shown by sCD40L level 
might fluctuate rapidly while lung damage shown by FVC 
level might be change in a slow progression.
Conclusion
Our study showed increased plasma soluble CD40 ligand 
concentrations in restrictive lung disease of systemic sclerosis 
patients. Our result found no significant correlation between 
sCD40L with FVC in SSc at dr. Hasan Sadikin General 
Hospital.
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